Tobin Schilke - Revance Therapeutics, CFO and Principal Financial Officer
| RVNCDelisted Stock | USD 3.65 0.00 0.00% |
CFO
Mr. Tobin C. Schilke is Chief Financial Officer and Principal Financial Officer, Principal Accounting Officer of the Company. He has served as our Chief Financial Officer since November 2018. Mr. Schilke served as Chief Financial Officer of Achaogen, Inc. from July 2016 through October 2018. From 2002 to June 2016, Mr. Schilke served in roles of increasing responsibility at the Roche Group, a pharmaceutical company, including serving as Finance Director and Company Director of Roche Products Limited in the United Kingdom from August 2014 to June 2016 and serving as Director of Genentech Commercial Finance BioOncology Business Unit from September 2012 to August 2014 since 2019.
| Age | 50 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Phone | 615 724 7755 |
| Web | https://www.revance.com |
Tobin Schilke Latest Insider Activity
Tracking and analyzing the buying and selling activities of Tobin Schilke against Revance Therapeutics, stock is an integral part of due diligence when investing in Revance Therapeutics,. Tobin Schilke insider activity provides valuable insight into whether Revance Therapeutics, is net buyers or sellers over its current business cycle. Note, Revance Therapeutics, insiders must abide by specific rules, including filing SEC forms every time they buy or sell Revance Therapeutics,'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Tobin Schilke over two weeks ago Insider Trading | ||
Tobin Schilke over six months ago Acquisition by Tobin Schilke of 145001 shares of Revance subject to Rule 16b-3 | ||
Tobin Schilke over six months ago Acquisition by Tobin Schilke of 1000 shares of Revance at 2.1845 subject to Rule 16b-3 | ||
Tobin Schilke over a year ago Disposition of 9361 shares by Tobin Schilke of Revance at 5.0426 subject to Rule 16b-3 |
Revance Therapeutics, Management Efficiency
The company has return on total asset (ROA) of (0.2436) % which means that it has lost $0.2436 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (20.9678) %, meaning that it created substantial loss on money invested by shareholders. Revance Therapeutics,'s management efficiency ratios could be used to measure how well Revance Therapeutics, manages its routine affairs as well as how well it operates its assets and liabilities.Revance Therapeutics, currently holds 478.43 M in liabilities with Debt to Equity (D/E) ratio of 2.94, implying the company greatly relies on financing operations through barrowing. Revance Therapeutics, has a current ratio of 3.31, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Revance Therapeutics,'s use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 4 records | CFO Age | ||
| Travis Coy | Immunocore Holdings | 45 | |
| Scott CPA | DiaMedica Therapeutics | 60 | |
| Mardi Dier | Madrigal Pharmaceuticals | 61 | |
| Timothy Sullivan | Apellis Pharmaceuticals | 54 | |
Management Performance
| Return On Equity | -20.97 | |||
| Return On Asset | -0.24 |
Revance Therapeutics, Leadership Team
Elected by the shareholders, the Revance Therapeutics,'s board of directors comprises two types of representatives: Revance Therapeutics, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Revance. The board's role is to monitor Revance Therapeutics,'s management team and ensure that shareholders' interests are well served. Revance Therapeutics,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Revance Therapeutics,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dwight JD, Chief Counsel | ||
| Dustin Sjuts, Vice President of Strategy and Sales | ||
| Conor Gallagher, Head Aesthetics | ||
| Jeanie Herbert, Sr. Director of Investor Relations | ||
| Mark Foley, CEO Director | ||
| Erica Jordan, Chief Officer | ||
| Azita Nejad, VP Operations | ||
| Dwight Moxie, Chief Counsel | ||
| Justin Ford, VP People | ||
| Amie Krause, Chief Officer | ||
| MD MBA, Chief Officer | ||
| Jessica Serra, Head ESG | ||
| Aubrey Rankin, Consultant | ||
| Tobin Schilke, CFO and Principal Financial Officer | ||
| Taryn Conway, Vice President of Marketing |
Revance Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Revance Therapeutics, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -20.97 | |||
| Return On Asset | -0.24 | |||
| Profit Margin | (0.72) % | |||
| Operating Margin | (0.54) % | |||
| Current Valuation | 680.39 M | |||
| Shares Outstanding | 104.39 M | |||
| Shares Owned By Insiders | 8.55 % | |||
| Shares Owned By Institutions | 87.45 % | |||
| Number Of Shares Shorted | 4.51 M | |||
| Price To Earning | (7.60) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Revance Stock
If you are still planning to invest in Revance Therapeutics, check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Revance Therapeutics,'s history and understand the potential risks before investing.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |